This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

This study has been completed.
Information provided by (Responsible Party):
Aileron Therapeutics Identifier:
First received: January 17, 2013
Last updated: May 29, 2013
Last verified: May 2013
The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.

Condition Intervention Phase
Growth Hormone Deficiency Drug: ALRN-5281 0.015 mg/kg Drug: ALRN-5281 0.05 mg/kg Drug: ALRN-5281 0.15 mg/kg Drug: Placebo 0.015 mg/kg Drug: Placebo 0.05mg/kg Drug: Placebo 0.15mg/kg Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers

Resource links provided by NLM:

Further study details as provided by Aileron Therapeutics:

Primary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Serum IGF-1 [ Time Frame: Predose, Day 1-Day 28 ]
  • Serum GH [ Time Frame: Predose, Day 1-Day 28 ]
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) of ALRN-5281 [ Time Frame: Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14 ]
  • Maximum plasma concentration (Cmax) of ALRN-5281 [ Time Frame: Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14 ]
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] [ Time Frame: Pre Dose, Day1- 0.5,1,2,3,4,6,8,10,12,14 and 16h post dose, Day2- Day11 and Day 14 ]
    AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)

Enrollment: 33
Study Start Date: January 2013
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ALRN-5281 0.015 mg/kg
Dosage-0.015 mg/kg
Drug: ALRN-5281 0.015 mg/kg
Experimental: ALRN-5281 0.05 mg/kg
Dosage- 0.05 mg/kg
Drug: ALRN-5281 0.05 mg/kg
Experimental: ALRN-5281 0.15 mg/kg
Dosage- 0.15 mg/kg
Drug: ALRN-5281 0.15 mg/kg
Placebo Comparator: Placebo 0.015 mg/kg
Dosage- 0.015 mg/kg
Drug: Placebo 0.015 mg/kg
Placebo Comparator: Placebo 0.05 mg/kg
Dosage- 0.05 mg/kg
Drug: Placebo 0.05mg/kg
Placebo Comparator: Placebo 0.15 mg/kg
Dosage - 0.15 mg/kg
Drug: Placebo 0.15mg/kg


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy male or female subjects aged 20 to 50 years, inclusive, at the time of informed consent.
  2. Subjects must be in good health as determined by the Investigator based on detailed medical history, physical examination, vital signs, clinical laboratory tests, ECGs and other screening evaluations.
  3. Ability to provide written informed consent and complying with all study requirements and restrictions.
  4. Is a non-smoker and non-tobacco user for a minimum of 6 months prior to screening

Exclusion Criteria:

  1. History or current evidence of any clinically significant cardiac, endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator
  2. Previous treatment with any GH Releasing Hormone (GHRH) analog.
  3. Participation in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to enrollment.
  4. History of cancer within the past five years (excluding non-melanoma skin cancer).
  5. History of alcohol or drug abuse or dependence within 12 months of screening as determined by the Investigator.
  6. Subjects with a body weight > 120 kg.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01775358

United States, Kansas
Vince and Associates Clinical Research, LLC
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
Aileron Therapeutics
Principal Investigator: Bradley D Vince, D.O. Vince and Associates
Study Director: Hubert C Chen, M.D. Aileron Therapeutics
  More Information

Responsible Party: Aileron Therapeutics Identifier: NCT01775358     History of Changes
Other Study ID Numbers: ALRN-100-01
Study First Received: January 17, 2013
Last Updated: May 29, 2013

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on September 18, 2017